MA43690A - Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers - Google Patents

Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers

Info

Publication number
MA43690A
MA43690A MA043690A MA43690A MA43690A MA 43690 A MA43690 A MA 43690A MA 043690 A MA043690 A MA 043690A MA 43690 A MA43690 A MA 43690A MA 43690 A MA43690 A MA 43690A
Authority
MA
Morocco
Prior art keywords
peptides
cancers
cell
combination
bladder cancer
Prior art date
Application number
MA043690A
Other languages
English (en)
Inventor
Jens Fritsche
Andrea Mahr
Oliver Schoor
Harpreet Singh
Colette Song
Toni Weinschenk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA43690A publication Critical patent/MA43690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
MA043690A 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers MA43690A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662302010P 2016-03-01 2016-03-01
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Publications (1)

Publication Number Publication Date
MA43690A true MA43690A (fr) 2021-06-02

Family

ID=55807140

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43090A MA43090A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
MA043690A MA43690A (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43090A MA43090A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers

Country Status (18)

Country Link
US (1) US10400011B2 (fr)
EP (2) EP3423085A1 (fr)
JP (2) JP2019516663A (fr)
KR (1) KR20180118702A (fr)
CN (1) CN109152825A (fr)
AU (2) AU2017227967B2 (fr)
BR (1) BR112018016734A2 (fr)
CA (1) CA3014848A1 (fr)
CO (1) CO2018008763A2 (fr)
CR (4) CR20210033A (fr)
EA (1) EA201891670A1 (fr)
GB (1) GB201603568D0 (fr)
IL (1) IL261266B2 (fr)
MA (2) MA43090A1 (fr)
MX (1) MX2018010167A (fr)
SG (3) SG10202008107QA (fr)
TW (1) TWI641617B (fr)
WO (1) WO2017148888A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
EP3606550A2 (fr) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Antigènes protéiques et leurs utilisations
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2019102710A1 (fr) * 2017-11-21 2019-05-31 尚史 三輪 Agent inhibiteur de métastases de cellules cancéreuses humaines et agent de détermination de cellules cancéreuses humaines
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
CN113538407B (zh) 2018-12-29 2022-10-14 北京市商汤科技开发有限公司 锚点确定方法及装置、电子设备和存储介质
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
EP3982980A4 (fr) * 2019-06-12 2023-11-29 BioNTech US Inc. Compositions de néoantigènes et utilisations associées
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN116333995A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于cxcr6阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
WO2022040631A1 (fr) 2020-08-21 2022-02-24 Immatics US, Inc. Procédés d'isolement de lymphocytes t sélectionnés cd8+
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4392441A1 (fr) 2021-08-24 2024-07-03 Immatics US, Inc. Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel
US12319720B2 (en) * 2021-08-31 2025-06-03 Washington University Neoantigen vaccines for triple negative breast cancer
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023081925A1 (fr) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Traitement combiné de thérapie cellulaire adoptive et compositions associées
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (fr) 2022-04-28 2023-11-02 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (fr) 2022-05-05 2025-03-12 Immatics US, Inc. Procédés d'amélioration de l'efficacité d'un lymphocyte t
CN115785206B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标07及其用途
CN115961032A (zh) * 2022-09-19 2023-04-14 深圳市罗湖区人民医院 一种膀胱癌相关突变基因的检测探针、检测试剂盒、突变质控品
EP4750806A1 (fr) 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Protéines de liaison à l'antigène dirigées contre mageb2
EP4750807A1 (fr) 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026033136A1 (fr) 2024-08-09 2026-02-12 Immatics Biotechnologies Gmbh Modalités de traitement avancées pour des cellules immunitaires modifiées par tcr anti-prame
WO2026096743A1 (fr) 2024-10-30 2026-05-07 Immatics US, Inc. Méthodes de fabrication de cellules t gamma delta

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444691A1 (fr) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
WO2003104429A2 (fr) 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes surexprimes par le cancer des ovaires et leur utilisation dans la mise au point de nouvelles therapies
DE602005020046D1 (de) * 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
ES2372709T3 (es) * 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
EP2336771A1 (fr) * 2009-12-16 2011-06-22 Universität Duisburg-Essen HAS3v2 en tant que marqueur de tumeur
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Also Published As

Publication number Publication date
CO2018008763A2 (es) 2018-08-31
AU2017227967A1 (en) 2018-09-06
SG10202110228YA (en) 2021-10-28
US20170253633A1 (en) 2017-09-07
IL261266B2 (en) 2023-10-01
AU2017227967B2 (en) 2021-03-25
CR20210034A (es) 2021-02-10
KR20180118702A (ko) 2018-10-31
CN109152825A (zh) 2019-01-04
BR112018016734A2 (pt) 2018-12-26
CA3014848A1 (fr) 2017-09-08
US10400011B2 (en) 2019-09-03
WO2017148888A1 (fr) 2017-09-08
SG10202008107QA (en) 2020-09-29
SG11201806951TA (en) 2018-09-27
EP3423085A1 (fr) 2019-01-09
JP2021129580A (ja) 2021-09-09
JP7201740B2 (ja) 2023-01-10
EA201891670A1 (ru) 2019-02-28
TWI641617B (zh) 2018-11-21
MX2018010167A (es) 2018-11-29
CR20210035A (es) 2021-02-10
AU2021204201A1 (en) 2021-07-15
IL261266A (en) 2018-10-31
MA43090A1 (fr) 2018-10-31
TW201734039A (zh) 2017-10-01
CR20180398A (es) 2018-11-30
EP3915577A1 (fr) 2021-12-01
CR20210033A (es) 2021-02-10
GB201603568D0 (en) 2016-04-13
JP2019516663A (ja) 2019-06-20
IL261266B1 (en) 2023-06-01
AU2021204201B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
MA42441B1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA53680A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA50925A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA44999A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre diverses tumeurs
MA45424A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MA43719A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
MA52115A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc et d'autres cancers
MA43399A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre la cll et d'autres cancers
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
IL261266A (en) Peptides, combination of peptides and drug-based cells for use in immunotherapy against bladder cancer and other types of cancer
MA47367A (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA51531A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA53033A (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA51170A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
HUE054453T2 (hu) Új peptidek és peptidkombinációk az emlõrák és más ráktípusok elleni immunterápiában történõ használatra
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA49158A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA49100A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
HUE065882T2 (hu) Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
EP3422945A4 (fr) Immunothérapie anticancéreuse améliorée par le biais d'une administration par patch à micro-aiguilles
MA46037A (fr) Nouveaux peptides et échafaudages destinés à être utilisés en immunothérapie contre le carcinome à cellules squameuses de la tête et du cou et d'autres cancers
MA45098A (fr) Nouveaux peptides, association de peptides en tant que cibles et destinés à être utilisés en immunothérapie contre le cancer de la vésicule biliaire et le cholangiocarcinome et autres cancers
MA49123A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
EP3442584A4 (fr) Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2